Experience of Using Tocilizumab in a Patient with Polyarticular Juvenile Rheumatoid Arthritis with Cervical Spine Lesions
https://doi.org/10.15690/pf.v12i4.1430
Abstract
The article describes a case of polyarticular juvenile idiopathic arthritis lesions of the cervical spine. This clinical example demonstrates the high efficiency of tocilizumab in a patient with polyarticular juvenile idiopathic arthritis with lesions of the cervical spine. After the first injection of tocilizumab a decrease in the following was observed: pain in the cervical spine and affected joints, severity of functional disorders in the temporomandibular joint and the interphalangeal joints, cervical spine; a 30% improvement in the JADAS, ACRpedi30 was achieved. By the 8th week of therapy the proliferative changes in the joints of the hands and arthralgia decreased, as well as the duration of morning stiffness. After 3 months there was a decrease in the activity of Jia (DAS28), and the erythrocyte sedimentation rate and serum concentrations of C-reactive protein. Adverse effects during therapy with tocilizumab were not observed. The disease activity decreased, (assessed using the visual analog scale (VAS)), as well as the functional impairment (assessed using the Children Health Assessment Questionnaire (CHAQ)). The emotional status and quality of life of the child and her family improved significantly.
About the Authors
E. A. Ligostaeva
Regional Сhildren’s Hospital, Rostov-na-Donu, Russian Federation
Russian Federation
Russian Federation
N. A. Curikova
Rostov State Medical University, Russian Federation
Russian Federation
Russian Federation
E. I. Alekseeva
Scientific Center of Children Health, RAMS, Moscow, Russian Federation
I.M. Sechenov First Moscow Medical State University, Russian Federation
Russian Federation
Russian Federation
S. E. Valieva
Scientific Center of Children Health, RAMS, Moscow, Russian Federation
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Center of Children Health, RAMS, Moscow, Russian Federation
Russian Federation
Russian Federation
T. V. Sleptsova
Scientific Center of Children Health, RAMS, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Насонов Е. Л. Генно-инженерные биологические препараты в лечении ревматоидного артрита. 2013. С. 123–136.
2. Алексеева Е. И., Литвицкий П. Ф. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотруд ников. Под общей ред. А. А. Баранова. М.: ВЕДИ. 2007. 368 с.
3. Cassidy J. T., Petty R. E. Textbook of pediatric rheumatology. New York, Edinburg, Melbourne, Tokyo. 2001.
4. McInnes I. B., Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2012; 365: 2205–19.
5. Smolen J. S., Aletaha D., Redlich R. The pathogenesis of rheumatoid arthritis: new insight from old clinical data? Nat Rev Rheumatol. 2012; 8: 235–43.
6. Ruperto N., Levinson J., Ravelli A. et al. Long-term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. Outcome status. J Rheumatol. 1997; 24 (5): 945–951.
7. Oliveira S., Ravelli A., Pistorio А. М. et al. Proxy-reported healthrelated quality of life of patients with juvenile rheumatoid arthritis: the Pediatric Rheumatology International Trials Organization multinational quality of life cohort study. Arthritis Rheum. 2007; 57 (1): 35–43.
8. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369 (9563): 767–778.
9. Малиевский В. А. Ювенильные артриты: эпидемиология, медико-социальные и экономические последствия, качество жизни. Автореф. дис. … докт. мед. наук: 14.00.39. Москва. 2006. 271 с.: ил.
10. Соболева Н. Г. Ювениальный ревматоидный артрит у детей Краснодарского края (особенности этиопатогенеза, оптимизация лечебной тактики). Автореф. дис. … докт. мед. наук: 14.00.09. Москва. 2009. 168 с.: ил.
11. Лигостаева Е. А. Особенности течения воспалительных заболеваний суставов у детей городской и сельской местности на примере Ростовской области. Автореф. дис. … канд. мед. наук: 14.01.08. Москва. 2010. 23 с.: ил.
12. Ravelli A., Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol. 2000; 27 (8): 1830–1833.
13. Ruperto N., Murray K. J., Gerloni V. et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50 (7): 2191–2201.
14. Алексеева Е. И., Бзарова Т. М. Ювенильный артрит: возможности медикаментозного и немедикаментозного лечения на современном этапе. Лечащий врач. 2011; 8.
15. Клинические рекомендации для педиатров: детская ревматология. Лекарственные средства, применяемые для лечения ревматических болезней у детей. Под ред. А. А. Баранова, Е. И. Алексеевой. 2011. С. 206–207.
16. Алексеева Е. И., Бзарова Т. М. Лечащий врач. 2011; 9: 60–6.
17. Зинчук И. Ю. Фарматека. 2014; 7: 77–82.
18. Lovell D. J., Giannini E. H., Reiff A. et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000; 342 (11): 763–769.
19. Lovell D. J., Reiff A., Ilowite N. T., Wallace C. A. et al. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with Juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58 (5): 1496–1504.
20. Horneff G., De Bock F., Foeldvari I., Girschick H. J. et al. Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis published online 15 Apr 2008. Doi:10.1136/ard.2007.087593.
21. Horneff G., Schmeling H., Goodman S. et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004; 63 (12):1638–1644.
22. Lovell D. J., Giannini E. H., Reiff A., Jones O. Y., Schneider R., Olson Ju.C, Stein L.D, Gedalia A., Ilowite N. T., Wallace C. A. et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 2003 Jan; 48 (1): 218–226.
23. Sato K., Tsuchiya M., Saldanha J. et al. Reshaping a human antibody to inhibit the inerieukin-6-dependent tumor cell growth. Cancer Res. 1993; 53: 851–6.
24. Nishimoto N., Yoshizaki R., Maeda K. et al. Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody, MRA, in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003; 30: 1426–35.
25. Emery P., Keystone E., Tony H.-P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis. 2008; 67: 1516–23.
26. Brunner H. I., Ruperto N., Zuber Z. et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomized, double-blind withdrawal trial. Ann Rheum Dis. 2014. P. 1–8.
Review
For citations:
Ligostaeva E.A., Curikova N.A., Alekseeva E.I., Valieva S.E., Bzarova T.M., Sleptsova T.V. Experience of Using Tocilizumab in a Patient with Polyarticular Juvenile Rheumatoid Arthritis with Cervical Spine Lesions. Pediatric pharmacology. 2015;12(4):467-470. (In Russ.) https://doi.org/10.15690/pf.v12i4.1430
Views:
693
Email this article 